Is Celldex (CLDX) Using Barzolvolimab’s Phase 3 Urticaria Bet To Redefine Its Core Strategy?

Simply Wall St.

2025/12/22

In December 2025, Celldex Therapeutics began a global Phase 3 EMBARQ-ColdU and SD trial of barzolvolimab in adults with cold urticaria and symptomatic dermographism who remain symptomatic despite H1 ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2593017346"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2593017346\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2593017346?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-12-22 02:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593017346","market":"us","top_or_hot":-1,"title":"Is Celldex (CLDX) Using Barzolvolimab’s Phase 3 Urticaria Bet To Redefine Its Core Strategy?","media":"Simply Wall St.","content":"<div>\n<p>In December 2025, Celldex Therapeutics began a global Phase 3 EMBARQ-ColdU and SD trial of barzolvolimab in adults with cold urticaria and symptomatic dermographism who remain symptomatic despite H1 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/is-celldex-cldx-using-barzolvolimabs-phase-3-urticaria-bet-t\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Celldex (CLDX) Using Barzolvolimab’s Phase 3 Urticaria Bet To Redefine Its Core Strategy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Celldex (CLDX) Using Barzolvolimab’s Phase 3 Urticaria Bet To Redefine Its Core Strategy?\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2025-12-22 02:21</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>In December 2025, Celldex Therapeutics began a global Phase 3 EMBARQ-ColdU and SD trial of barzolvolimab in adults with cold urticaria and symptomatic dermographism who remain symptomatic despite H1 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/is-celldex-cldx-using-barzolvolimabs-phase-3-urticaria-bet-t\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/is-celldex-cldx-using-barzolvolimabs-phase-3-urticaria-bet-t\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLDX","symbol_name":"塞德斯醫療","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/is-celldex-cldx-using-barzolvolimabs-phase-3-urticaria-bet-t","article_id":"2593017346","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/is-celldex-cldx-using-barzolvolimabs-phase-3-urticaria-bet-t","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2593017346","pubTimestamp":1766341277,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In December 2025, Celldex Therapeutics began a global Phase 3 EMBARQ-ColdU and SD trial of barzolvolimab in adults with cold urticaria and symptomatic dermographism who remain symptomatic despite H1 antihistamines or biologics, enrolling about 240 patients across approximately 75 sites in 7 countries with complete response at Week 12 as the primary endpoint.\nThis late-stage program builds directly on earlier placebo-controlled Phase 2 data showing rapid, durable clinical responses and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLDX":"塞德斯医疗","BK4139":"生物科技"},"translate_title":"Celldex(CLDX)是否正在利用Barzolvolimab的3期荨麻疹赌注来重新定义其核心战略？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLDX":1.5},"content_text":"In December 2025, Celldex Therapeutics began a global Phase 3 EMBARQ-ColdU and SD trial of barzolvolimab in adults with cold urticaria and symptomatic dermographism who remain symptomatic despite H1 antihistamines or biologics, enrolling about 240 patients across approximately 75 sites in 7 countries with complete response at Week 12 as the primary endpoint. This late-stage program builds directly on earlier placebo-controlled Phase 2 data showing rapid, durable clinical responses and meaningful quality-of-life improvements in these highly burdened chronic inducible urticaria populations. We’ll now examine how advancing barzolvolimab into a global Phase 3 program for hard-to-treat urticaria shapes Celldex’s investment narrative. Uncover the next big thing with financially sound penny stocks that balance risk and reward.What Is Celldex Therapeutics' Investment Narrative?To own Celldex today, you really have to believe barzolvolimab can convert strong mid‑stage data into a real commercial franchise across multiple urticaria settings, and eventually beyond. The EMBARQ Phase 3 launch is a clear step toward that, and while the market’s recent muted share price reaction suggests expectations were already reasonably high, it still sharpens near to medium term catalysts around Phase 3 readouts, partnering potential and financing needs. At the same time, the company’s small revenue base, sizeable losses of over US$200,000,000 in the last reported twelve months, and forecasts for continued unprofitability keep funding risk very much in focus. This new trial raises Celldex’s execution bar: success could reshape the story, but setbacks would matter. However, one key funding risk could catch shareholders off guard if timelines slip.\n\nUpon reviewing our latest valuation report, Celldex Therapeutics' share price might be too optimistic.Exploring Other PerspectivesCLDX 1-Year Stock Price Chart The single Simply Wall St Community fair value at US$53.36 underlines how thin retail valuation coverage still is. Set that against Celldex’s heavy losses and ongoing cash needs, and you can see why opinions on future performance may differ sharply.Explore another fair value estimate on Celldex Therapeutics - why the stock might be worth just $53.36!Build Your Own Celldex Therapeutics NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Celldex Therapeutics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.Our free Celldex Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Celldex Therapeutics' overall financial health at a glance.Want Some Alternatives?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.The New Payments ETF Is Live on NASDAQ:Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.Explore how this launch could reshape portfoliosSponsored ContentNew: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}